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In recent years, several important advances have been made in our understanding
of the pathways that lead to cell dysfunction and death in Parkinson’s disease (PD)
and Huntington’s disease (HD). Despite distinct clinical and pathological features, these
two neurodegenerative diseases share critical processes, such as the presence of
misfolded and/or aggregated proteins, oxidative stress, and mitochondrial anomalies.
Even though the mitochondria are commonly regarded as the “powerhouses” of the cell,
they are involved in a multitude of cellular events such as heme metabolism, calcium
homeostasis, and apoptosis. Disruption of mitochondrial homeostasis and subsequent
mitochondrial dysfunction play a key role in the pathophysiology of neurodegenerative
diseases, further highlighting the importance of these organelles, especially in neurons.
The maintenance of mitochondrial integrity through different surveillance mechanisms
is thus critical for neuron survival. Mitochondria display a wide range of quality control
mechanisms, from the molecular to the organellar level. Interestingly, many of these
lines of defense have been found to be altered in neurodegenerative diseases such
as PD and HD. Current knowledge and further elucidation of the novel pathways that
protect the cell through mitochondrial quality control may offer unique opportunities for
disease therapy in situations where ongoing mitochondrial damage occurs. In this review,
we discuss the involvement of mitochondrial dysfunction in neurodegeneration with a
special focus on the recent findings regarding mitochondrial quality control pathways,
beyond the classical effects of increased production of reactive oxygen species (ROS)
and bioenergetic alterations. We also discuss how disturbances in these processes
underlie the pathophysiology of neurodegenerative disorders such as PD and HD.
Keywords: Parkinson’s disease, Huntington’s disease, mitochondrial quality control, mitochondrial dysfunction,
neurodegeneration
Franco-Iborra et al. Mitochondrial Quality Control in Neurodegenerative Diseases
MITOCHONDRIAL DYSFUNCTION: A
COMMON FEATURE IN
NEURODEGENERATIVE DISORDERS
Despite distinct clinical and pathological features,
neurodegenerative diseases share critical processes such as
(i) the presence of misfolded and/or aggregated proteins;
(ii) neuroinflammation; (iii) impairment of autophagy; (iv)
oxidative stress; and (v) mitochondrial anomalies. Neurons
are highly dependent on mitochondrial function to maintain
energy-intensive functions such as membrane excitability,
neurotransmission, and plasticity: the brain consumes 20% of
the total oxygen and about a quarter of the total glucose used by
the body for energy supply.
Parkinson’s Disease
Parkinson’s disease (PD) is the second most prevalent
neurodegenerative disorder, affecting 1–3% of the population
over 65 years of age. Most PD patients are diagnosed as sporadic
patients with idiopathic PD, occurring from complex interactions
between environmental and genetic factors. The main features
of this pathology are motor alterations such as resting tremor,
postural instability, rigidity and bradykinesia, and non-motor
symptoms like fatigue, depression, anxiety, sleep and autonomic
disturbances, decreased motivation, apathy, decline in cognition
and dementia. The neuropathological hallmarks of PD include
loss of dopaminergic neurons in the midbrain substantia nigra
pars compacta (SNpc) and accumulation of Lewy bodies (LBs)
containing α-synuclein.
The first evidence linking mitochondrial dysfunction
and PD was the discovery that MPTP (1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine), an inhibitor of complex I
(NADH/ubiquinone oxidoreductase) of the mitochondrial
electron transport chain, causes parkinsonism in humans
(Langston et al., 1983). Later, sporadic PD patients were reported
to present reduced complex I activity, not only in the SNpc
(Schapira et al., 1990) but also in other brain areas and peripheral
tissues (Parker et al., 1989, 2008; Krige et al., 1992; Blin et al.,
1994; Haas et al., 1995), as well as in cytoplasmic hybrid (cybrid)
cells (Swerdlow et al., 1996) derived from PD patients (Figure 1).
Besides the mitochondrial complex I defect, genetic evidence
suggests that mutations in mitochondrial DNA (mtDNA) also
play a role in the pathogenesis of PD. Haplogroups J and K have a
protective effect against PD in certain European populations (van
der Walt et al., 2003; Fachal et al., 2015), whereas haplogroup
HV has been reported to increase the risk of PD in Caucasians
(Hudson et al., 2013). Alterations in mtDNA have long been
hypothesized to play a pathogenic role in PD. In particular,
multiple mtDNA deletions have been observed in SNpc
dopaminergic neurons from post-mortem human brains of both
aged individuals and patients with idiopathic PD (Bender et al.,
2006; Kraytsberg et al., 2006). Mutations in mitochondrial DNA
polymerase gamma (POLG), which result in the accumulation
of multiple mtDNA deletions in muscle, have been associated
with levodopa-responsive parkinsonism with severe SNpc
dopaminergic neuronal loss, usually as part of a more complex
syndrome (Luoma et al., 2004; Davidzon et al., 2006). Our group
and others showed that despite high levels of mtDNA deletions,
SNpc dopaminergic neurons from POLG mutant mice did not
exhibit gross mitochondrial dysfunction or degeneration (Perier
et al., 2013; Dai et al., 2014), indicating that a high level of
mtDNA deletions is not sufficient per se to trigger cell death in
SNpc dopaminergic neurons. In contrast, partial depletion of
mtDNA in mice by a conditional disruption in dopaminergic
neurons of mitochondrial transcription factor A (TFAM), which
regulates mtDNA transcription, leads to a decrease in mtDNA
content and cytochrome c oxidase enzymatic activity, which is
associated with a progressive parkinsonism phenotype (Ekstrand
et al., 2007). These findings strongly support a role of respiratory
chain and mitochondrial dysfunction in the pathogenesis of PD.
A primary role of mitochondrial dysfunction in this process
was boosted by the identification of genes related to familial
forms of PD: α-synuclein (SNCA), leucine-rich repeat kinase 2
(LRRK2), PTEN-induced putative kinase 1 (PINK1), parkin RBR
E3 ubiquitin protein ligase, also known as Parkin, (PRKN), DJ-
1 (PARK7), and vacuolar sorting protein 35 (VPS35; Figure 1).
Mutations in SNCA, LRRK2, and VPS35 are associated with
autosomal dominant PD. Several missense mutations have been
linked to α-synuclein (A53T, A30P, E46K, H50Q, and A53E)
and some families also present duplications and triplications of
the SNCA wild-type gene (Polymeropoulos et al., 1997; Krüger
et al., 1998; Singleton et al., 2003; Zarranz et al., 2004; Appel-
Cresswell et al., 2013; Proukakis et al., 2013; Pasanen et al.,
2014). SNCA mutations have been linked to increased mtDNA
damage, mitophagy, and mitochondrial fission, among others
(Wong and Krainc, 2017). For example, the A53T mutation
leads to increased mitochondrial fission (Xie and Chung, 2012;
Pozo Devoto et al., 2017) and mitophagy (Chinta et al., 2010;
Choubey et al., 2011; Chen et al., 2015). LRRK2 mutations are
the major cause of familial PD (Paisán-Ruiz et al., 2004; Zimprich
et al., 2004), with more than 50 mutations identified thus far, the
most common of which affects the kinase activity of the protein
(Nuytemans et al., 2010). LRRK2 mutations in Caenorhabditis
elegans and neurons derived from induced pluripotent stem
cells are associated with mitochondrial dysfunction and altered
mitochondrial dynamics (Saha et al., 2009; Wang et al., 2012).
Mutations inVPS35 have been recently described (Vilariño-Güell
et al., 2011; Zimprich et al., 2011), and may cause abnormal
trafficking of cargo by mitochondrial-derived vesicles (MDVs)
(Wang et al., 2015), these being cargo-selective vesicles that bud
off mitochondria independently from the mitochondrial fission
machinery (Neuspiel et al., 2008).
PINK1, a serine/threonine kinase, and Parkin, an E3 ubiquitin
ligase, work together in a common pathway leading to the
clearance of dysfunctional mitochondria (Pickrell and Youle,
2015). Mutations in PINK1 and Parkin gene are associated with
recessive PD (Kitada et al., 1998; Valente et al., 2004). Parkin
loss in mice and Drosophila flies leads to decreased complex
I and complex IV activities (Palacino et al., 2004; Casarejos
et al., 2006), with Drosophila flies exhibiting locomotor defects,
reduced lifespan, mitochondrial abnormalities and dopaminergic
neuron degeneration (Greene et al., 2003). In cell lines, loss of
PINK1 or mutations therein lead to decreased mitochondrial
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FIGURE 1 | Mitochondrial dysfunction in PD and HD. (A) Reduced complex I activity is a classical hallmark of the pathogenesis of PD, with a subsequent
increased production of mitochondrial-derived ROS. Increased ROS is accompanied by mtDNA damage and bioenergetic failure. Further highlighting the role of
mitochondrial dysfunction in PD, many of the mutated nuclear genes linked to familial forms of the disease, including PINK1 (phosphatase, and tensin
homolog-induced kinase 1), Parkin, α-synuclein, DJ-1, and LRRK2 (leucine-rich-repeat kinase 2), have been shown to affect many of these mitochondrial features
(see main text for details). (B) Mutant huntingtin (mHtt) inhibits the activity of succinate dehydrogenase enzyme of complex-II of mitochondria, which may account for
the bioenergetic deficit present in HD. Moreover, mHtt protein directly impairs the ability of PGC-1α to activate downstream target genes involved in mitochondrial
biogenesis and normal mitochondrial function. Further amplifying the damage, mHtt is able to promote calcium-dependent mitochondrial depolarization and
mitochondrial swelling. Mitochondrial transport is also impaired due to the ablity of mHtt to combines specifically with the beta subunit of tubulin.
respiration and decreased ATP synthesis (Liu et al., 2009).
DJ-1 mutations also cause autosomal recessive PD (Thomas
and Beal, 2007) leading to impaired mitochondrial respiration,
reduced membrane potential, increased ROS levels and altered
mitochondrial morphology (Krebiehl et al., 2010).
Huntington’s Disease
Huntington’s disease (HD) is a devastating neurodegenerative
disease affecting 10.6–13.7 individuals per 100,000 people in
Western populations (Bates et al., 2015). It is an autosomal
dominant neurodegenerative disorder, characterized by the
abnormal expansion of the cytosine, adenine, and guanine
(CAG) triplet repeats in the polyglutamine region of the
huntingtin (HTT) gene. Clinically, HD is characterized by motor
dysfunction, cognitive decline, and psychiatric disturbances
caused by the preferential atrophy of GABAergic medium spiny
neurons in the striatum as well as in other regions such as the
cerebral cortex (McColgan and Tabrizi, 2018). How the mutant
huntingtin protein elicits its toxic effects remains elusive, but
several lines of evidence suggest involvement of transcriptional
dysregulation and impaired mitochondrial function in the
pathogenesis of HD (Labbadia and Morimoto, 2013; Figure 1).
Bioenergetics has been a classical field of study in HD
research since the discovery of glucose hypometabolism in the
caudate nuclei of presymptomatic HD subjects (Grafton et al.,
1992). Both HD patients and presymptomatic carriers present
increased lactate levels in brain areas linked with the disease
(Jenkins et al., 1993), which is indicative of impaired energy
metabolism. Interestingly, the presence of metabolic alterations
in presymptomatic carriers argues in favor of mitochondrial
dysfunction as an early appearing defect in the disease. As
for PD and complex I, HD is linked to reduced complex II
and complex III activity in the striatum, with complex IV
also being affected to a lesser extent (Brennan et al., 1985;
Gu et al., 1996). Accidental intoxication is also capable of
recapitulating some of the clinical and pathologic phenotypes of
HD in humans (Ludolph et al., 1991). Indeed, intoxication with
mildewed sugar cane contaminated with 3-nitropropionic acid
(3-NPA), an inhibitor of the succinate dehydrogenase enzyme
of complex II, is able to induce HD symptoms in rodents
and non-human primates (Brouillet et al., 2005). Studies have
also suggested the involvement of mtDNA mutations in HD
pathogenesis, as an increased frequency of mtDNA lesions
and mtDNA depletion are also found in the HD striatum
and skin fibroblasts (Siddiqui et al., 2012). How mitochondrial
dysfunction and bioenergetic defects in HD occur is still a
matter of debate. Nonetheless, mutant huntingtin is capable
of directly interacting with the outer mitochondrial membrane
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(OMM) (Gutekunst et al., 1998; Choo et al., 2004; Orr et al.,
2008), reinforcing the notion that mutant huntingtin directly
impairs mitochondrial function. Further linking mitochondrial
dysfunction and HD is the ability of mutant huntingtin
to inhibit peroxisome proliferator-activated receptor gamma
coactivator 1-α (PGC-1α) expression (Figure 1). PGC-1α is
a transcriptional coactivator that regulates several metabolic
processes such as mitochondrial biogenesis, thermogenesis
or oxidative phosphorylation (OXPHOS) (Puigserver and
Spiegelman, 2003). Mutant huntingtin interferes with the PGC-
1α transcriptional pathway, impairing its ability to activate
downstream genes, while PGC-1α ectopic expression provides
neuroprotection in transgenic HDmice and in the 3-NPAmouse
model (Cui et al., 2006; Weydt et al., 2006).
Beyond bioenergetics, mitochondria also regulate calcium
homeostasis. Panov et al. (2002) demonstrated that lymphoblast
mitochondria from HD patients have a lower membrane
potential and depolarize at lower calcium loads compared
to control mitochondria. This defect was also present in
brain mitochondria from a HD transgenic mouse model
(Panov et al., 2002). Cyclosporine treatment, which inhibits
mitochondrial permeability transition pore (mPTP) opening, was
able to delay this effect (Quintanilla et al., 2013), supporting
a role for dysfunctional mitochondrial calcium handling in the
pathogenesis of HD.
Considering the important role that mitochondrial
function plays in neuronal homeostasis, some endogenous
mechanisms have evolved to maintain mitochondrial integrity
and functionality. These mechanisms can be divided into
different categories, and although they respond to similar cues,
the degree of damage determines their sequential activation.
Upon excessive production of reactive oxygen and nitrogen
species, for example, the first level of defense takes place with
a coordinated detoxifying network. The second level of defense
maintains the integrity of the mitochondrial proteome, while
the third level controls organellar shape and number through
interconnected processes such as mitochondrial fusion, fission
and mitophagy. In this review article, we focus attention
on the role of mitochondrial quality control processes that
are responsible for maintaining mitochondrial integrity and
functionality, and how these mechanisms may be functionally
disturbed in PD and HD.
MITOCHONDRIA, THE SOURCE, AND
TARGET OF ROS: MECHANISMS FOR
KEEPING THEM HEALTHY
The term oxidative stress describes conditions that result
from the imbalance between free radical generation, their
detoxification and elimination.Mitochondria are themain source
of cellular reactive oxygen species (ROS) as well as having the
highest antioxidant capacity (Figure 2). The harmful effects of
ROS involve damage to macromolecules such as proteins, lipids,
polysaccharides, or nucleic acids. The intrinsic properties of
neurons, i.e., (i) high metabolic rates; (ii) a rich composition
of fatty acids prone to peroxidation; (iii) high intracellular
concentrations of transition metals, capable of catalyzing the
formation of reactive hydroxyl radicals; (iv) low levels of
antioxidants; and (v) reduced capability to regenerate, make
them highly vulnerable to the detrimental effects of ROS. Under
normal conditions, small amounts of molecular oxygen in the
mitochondria are reduced to ROS rather than being converted
into water. Because of its high metabolic rate, the brain consumes
high levels of oxygen, leading to increased radical formation.
Thus, the presence of antioxidant defenses to reduce ROS levels
below a toxic threshold is fundamental. The superoxide radical
(•O−2 ) is the first radical that appears with the reduction of
molecular oxygen. It can be transformed into hydrogen peroxide
(H2O2) by the action of the enzyme superoxide dismutase (SOD).
Hydrogen peroxide is poorly reactive with most biomolecules,
but it can react with Fe2+ (in the Fenton reaction) to give rise
to the hydroxyl radical (OH•), probably the most reactive free
radical found in vivo (Halliwell and Gutteridge, 1984; Liochev,
2013), which can react with virtually all biomolecules. To
maintain a balanced level of reactive species, cells have developed
various antioxidant defenses, the first being SOD (superoxide
dismutase), which accelerates the dismutation of two molecules
of superoxide into one molecule of H2O2 and one molecule
of O2, thus, reducing the potentially harmful effects of •O
−
2 .
Three SOD isoenzymes have been identified in humans: copper
and zinc-containing SOD (CuZnSOD/SOD1), mainly located in
the cytosol and nuclear compartments; manganese-containing
SOD (MnSOD/SOD2), a mitochondrial enzyme; and SOD3, a
MnSOD located extracellularly (Perry et al., 2010). Even though
H2O2 is a radical with low reactivity, it must be eliminated by
the action of enzymes such as catalase, glutathione peroxidases
(GPXs), the thioredoxin system, peroxiredoxins (PRDX), and
glutaredoxins. GPX couples the reduction of H2O2 (and other
peroxides) to H2O (or to corresponding alcohols) with the
oxidation of reduced glutathione (GSH) to oxidized glutathione
(GSSG), which can be converted back to GSH by glutathione
reductase (GR). PRDX also couples the reduction of H2O2 with
a cycle of peroxide-dependent oxidation and thiol-dependent
reduction of cystein residues, the latter catalyzed by thioredoxin
and thioredoxin reductase. Glutaredoxins have the same function
as the thioredoxin system (Chance et al., 1979; Rhee et al., 2005).
Glutathione S-transferases participate in the detoxification of
electrophilic compounds by their conjugation with GSH (Hayes
et al., 2005). Another group of non-enzymatic antioxidants such
as glutathione, ascorbic acid (vitamin C), α-tocopherol (vitamin
E), carotenoids, or flavonoids, which are mainly ingested with
the diet, act by scavenging free radicals (Forman et al., 2014).
The last antioxidant defense layer is the sequestration of “free”
transition metals, such as iron or copper, which are capable of
stimulating free radical formation and also the direct oxidation of
macromolecules.Within cells, iron is stored in the form of ferritin
and copper as metallothionein (Rutherford and Bird, 2004).
Oxidative Stress and Parkinson’s Disease
It is now clear that complex I inhibition-induced mitochondrial
dysfunction causes the chronic production of ROS and is
instrumental in the demise of dopaminergic neurons. Some
catalytic subunits of complex I have been found to be oxidized in
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FIGURE 2 | Oxidative stress is thought to be the common underlying mechanism that leads to cellular dysfunction and eventual cell death. (A) Oxidants and
superoxide radicals are produced as by-products of oxidative phosphorylation, making mitochondria the main site of reactive oxygen species (ROS) generation within
the cell. (B) Dopamine can be oxidized to reactive dopamine quinones, contributing to increased levels of ROS. (C) Oxidative stress occurs when there is an
imbalance between ROS production and cellular antioxidant activity. Excessive ROS causes lipid peroxidation, DNA damage and protein oxidation. Accumulation of
free radicals causes mitochondrial dysfunction and contributes to the propagation of stress related to neuronal pathophysiology.
PD brain (Keeney et al., 2006), which represents a feed-forward
cycle in which complex I inhibition produces ROS, which in turn
impacts on complex I activity. Oxidative damage to proteins,
lipids and DNA has been observed in post-mortem brain samples
from PD patients (Dauer and Przedborski, 2003). Supporting a
pathogenic role for mitochondria-derived ROS in the context
of PD, transgenic mice overexpressing human catalase (an
antioxidant enzyme normally localized in the peroxisome)
specifically targeted to themitochondria exhibit an attenuation of
MPTP-induced mitochondrial ROS and reduced dopaminergic
cell death (Perier et al., 2010). Moreover, oxidation-mediated
damage to mitochondrial components, such as optic atrophy 1
(OPA1), contributes to PD neurodegeneration by remodeling the
mitochondrial structure and cristae organization. Such cristae
remodeling associated with cardiolipin peroxidation induces
cytochrome c release and subsequent activation of apoptosis
(Perier et al., 2005; Ramonet et al., 2013).
The SNpc is particularly sensitive to oxidative stress, probably
because of its unique dopaminergic environment. Dopamine
is vulnerable to auto- and/or enzymatic oxidation, producing
reactive dopamine quinone, and ROS (Figure 2; Graham et al.,
1978; Maker et al., 1981). Dopamine-induced toxicity has been
observed in several in vitro and in vivo models (Hastings et al.,
1996), and has been reported to affect several proteins, among
them complex I (Ben-Shachar et al., 2004). Recently, it was shown
that dopaminergic neurons derived from idiopathic and familial
PD patients had decreased basal respiration and accumulation of
oxidized dopamine. Interestingly, the treatment of those neurons
with isradipine, a Cav1 channel antagonist, or a calcineurin
inhibitor was able to decrease oxidized dopamine levels (Burbulla
et al., 2017), highlighting the important role of calcium in
dopamine oxidation. Besides, the expression of constitutively
open Cav1.3 channels has been suggested to render nigrostriatal
neurons more vulnerable to excitotoxic cell death. SNpc neurons
are able to generate action potentials in the absence of synaptic
input (Romo and Schultz, 1990). For their pacemaking activity,
SNpc neurons not only engage monovalent cation channels but
also L-type calcium channels with a distinctive Cav1.3, that
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allow calcium entry into the cytoplasm (Ping and Shepard,
1996). The engagement of Cav1.3 calcium channels comes
at a metabolic cost for the neurons, since they have to
pump calcium back through ATP-dependent pumps (Wilson
and Callaway, 2000). A key paper by Guzman et al. (2010)
showed how L-type calcium channels induce oxidative stress
specific to SNpc dopaminergic neurons, which exhibit higher
levels of basal oxidation compared to dopaminergic ventral
tegmental area (VTA) neurons. Antagonizing L-type calcium
channels lowered the oxidation state of SNpc dopaminergic
neurons, but not VTA neurons. Moreover, blocking calcium
entry into the mitochondria also decreased oxidation (Guzman
et al., 2010). Interestingly, oxidative stress is amplified in SNpc
dopaminergic neurons from DJ-1 KO mice. These mice exhibit
decreased mRNA levels of two UCPs (uncoupling protein), Ucp4
and Ucp5, in the SNpc leading to a blunted UCP-mediated
mitochondrial uncoupling, which could explain the increased
oxidation state (Guzman et al., 2010). Taken together, this
work suggests that SNpc dopaminergic neurons have higher
basal oxidation states, which is a consequence of the activation
of L-type calcium channels during autonomous pacemaking.
Additionally, SNpc dopaminergic neurons have also a relatively
large axonal arborization (Matsuda et al., 2009), increasing their
bioenergetic demands and rendering them more susceptible to
ROS production. Pacelli et al. (2015) showed that SNpc neurons
have a higher oxygen consumption rate and a lower maximal
capacity together with increased ROS levels compared to VTA
neurons, due to their larger axonal arborization. Neurons with
smaller arborization size were less susceptible to die from the
toxic effects of complex I inhibitors such as MPP+ or rotenone
(Pacelli et al., 2015).
Not only are SNpc dopaminergic neurons more vulnerable
to oxidative stress, but PD neuropathogenesis is associated with
alterations in the antioxidant defense system (Figure 2). SOD2
activity in PD post-mortem tissue is increased, highlighting
the mitochondria as one of the main sites of ROS production
(Saggu et al., 1989; Poirier et al., 1994). SOD1 and α-synuclein
co-deposition with Lewy pathology has also been reported
(Nishiyama et al., 1995), together with an upregulation of SOD1
(Marttila et al., 1988). Degenerating neurons exhibit reduced
intracellular copper levels (Davies et al., 2014), which renders
the SOD1 metal-deficient isoform more prone to aggregate. This
vicious circle is then fed with reduced copper metallation of
SOD1, decreasing its enzymatic function on the one hand and
upregulating oxidative stress-induced SOD1 on the other. As a
result, SOD1 aggregates increase, rendering SNpc neurons more
vulnerable to oxidative stress (Trist et al., 2017). Additionally,
GSH content is decreased in the SNpc post-mortem tissue of PD
patients (Sian et al., 1994). Metal homeostasis is also dysregulated
in PD patients, who display a higher content of iron in the
SNpc compared to age-matched controls (Dexter et al., 1989).
Increased levels of iron can stimulate free radical formation
through the Fenton reaction, leading to the generation of highly
reactive OH• radicals. Interestingly, iron chelation was shown
to be neuroprotective against MPTP-induced dopaminergic cell
death (Kaur et al., 2003).
Oxidative Stress and Huntington’s Disease
Several markers of oxidative stress were found in post-mortem
tissue of HD patients; these include (i) lipofuscin accumulation,
(ii) presence of the classical marker of oxidative modification
in proteins (protein carbonyls) and lipids (malondialdehyde and
4-hydroxynonenal), and (iii) markers of oxidative damage to
nuclear DNA, such as 8-hydroxydeoxyguanosine (Browne et al.,
1997; Stack et al., 2008).
HD neuropathogenesis is also associated with alterations
in the antioxidant defense system (Figure 2). Glutathione is
decreased in the cerebral cortex from HD patients (Beal et al.,
1992), whereas antioxidant enzymes, such as peroxiredoxin
and GPX, together with the activity of SOD2 and catalase,
were reported to be increased in the post-mortem human
HD striatum (Sorolla et al., 2008). In general, the enhanced
activity of antioxidants reduces neuronal oxidative stress by
maintaining ROS at nanomolar levels, indicating that only
neurons with higher antioxidant capacity are able to survive.
Impairment of antioxidant defenses renders proteins, among
other biomolecules, more prone to oxidation. In HD, the
enzyme aconitase is one of the most affected enzymes of the
tricarboxylic acid cycle (TCA), probably due to its Fe-S clusters.
Aconitase oxidation is accompanied by decreased activity in
the HD caudate, putamen and cerebral cortex (Tabrizi et al.,
1999). Importantly, aconitase inactivation directly correlates
with the generation of superoxide produced by excitotoxicity
(Patel et al., 1996). Moreover, mitochondrial creatine kinase,
citrate synthase, and ATP synthase are also oxidized in
the striatum of HD patients, leading to a reduced catalytic
activity (Sorolla et al., 2010) and providing a link between
oxidative stress and the characteristic bioenergetic deficit present
in HD.
Several neuroimaging studies suggest an increased iron signal
in the basal ganglia of HD patients (Muller and Leavitt, 2014),
which was confirmed by biochemical and histochemical evidence
(Dexter et al., 1991), although the findings have some limitations.
Another study identified that not only iron but also copper
increases in R6/2 transgenic mice (expressing truncated N-
terminal fragments of mutant huntingtin with 144 CAG repeats),
which would contribute to creating a toxic microenvironment
in HD pathology (Fox et al., 2007). Iron-containing proteins
also become altered in HD (Muller and Leavitt, 2014). Succinate
dehydrogenase, the main component of complex II, displayed
decrease expression of its Fe-S subunit Ip and subunit Fp in
human post-mortem tissue and in a HD cellular model. Reduced
expression of those subunits was accompanied by a decrease
in succinate dehydrogenase catalytic activity (Benchoua et al.,
2006).
Taken together, these data highlight that antioxidant defense
mechanisms are hampered in the context of PD and HD,
with specific enzymes being altered in each pathology, but
always leading to a scenario in which the balance between ROS
production and scavenging is altered. This breakdown can have
important implications in the pathology of neurodegenerative
disorders, amplifying the detrimental cascade and generating
new defects.
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MITOCHONDRIAL PROTEIN QUALITY
CONTROL: THE GUARANTEE OF
MITOCHONDRIAL HEALTH
The endosymbiotic hypothesis argues that the mitochondrion
evolved from a bacterial ancestor within the phylum
Alphaproteobacteria through a symbiotic process within a
eukaryotic host cell (Margulis, 1970). Mammalian mitochondria
have a ∼16-kb genome encoding for 13 protein subunits
of the mitochondrial electron transport chain and ATP
synthase, as well as the ribosomal RNA (rRNA) and transfer
RNA (tRNA) components of the mitochondrial translation
system (Anderson et al., 1981). This means that most of the
mitochondrial proteome is encoded in the nucleus, synthesized
in the cytosol, and imported into the organelle. Most nuclear-
encoded mitochondrial proteins are synthesized as precursors
and maintained in an unfolded conformation to make them
translocation-competent. Precursor proteins in the cytosol
must exist in complexes with cytosolic chaperones, such as
HSP70 and HSP90, to avoid their degradation and aggregation
(Young et al., 2003). Moreover, those precursors need to
contain information that directs them to the mitochondria
and into the correct mitochondrial compartment. The most
common signal is the N-terminal targeting sequence called
mitochondrial-targeting sequence (MTS), which consists of
10–80 amino acid residues with no sequence identity, but with
some characteristic physicochemical properties, such as its
potential to form amphipathic helices with one hydrophobic
and one positively charged face (Roise et al., 1986; Pfanner et al.,
2000) The MTS is normally cleaved in the matrix leading to
the mature polypeptide. There are also C-terminal targeting
sequences and internal signals whose purpose remains elusive
(Gordon et al., 2000). Most mitochondrial proteins are located
within the matrix; for these proteins to be imported, there
needs to be cooperation between the two main mitochondrial
translocases—the translocase of the outer membrane (TOM)
complex on the outer membrane, formed by seven components
(Tom70, Tom22, Tom20, Tom40, Tom5, 6, and 7) (Model et al.,
2008; Bausewein et al., 2017), and the translocase of the inner
membrane (TIM23) complex (Tim50, Tim17, Tim21, Tim23,
Tim44, Pam 17, Tim16/Pam16, Tim14/Pam18, mtHSP70, and
Mge1) (Mokranjac and Neupert, 2010). The TOM complex
mediates the translocation of nearly all of the mitochondrial
proteome, whereas the TIM23 complex translocates pre-proteins
through the inner mitochondrial membrane. Translocation
through the TIM23 complex requires an intact mitochondrial
membrane potential and the hydrolysis of ATP. The inner
mitochondrial membrane harbors a variety of proteins,
including the mitochondrial electron transport chain complexes
and ATP synthase. There are three different routes for the
import of inner mitochondrial membrane proteins once they
have been translocated by the TOM complex: (1) through the
TIM22 complex located in the inner mitochondrial membrane,
(2) through a lateral insertion by the TIM23, complex, and (3)
in an export-like route from the matrix to the inner membrane
(Wiedemann and Pfanner, 2017).
Changes in the stoichiometric balance between nuclear- and
mitochondrial-encoded proteins due to improper mitochondrial
protein import and folding, as well asmutations inmtDNA, affect
organelle proteostasis (Houtkooper et al., 2013). This is sufficient
to disrupt the integrity and functionality of mitochondria.
Mitochondrial protein import is thus under the surveillance
of molecular chaperones (proteins that stabilize or assist the
acquisition of the active conformation of other proteins without
being part of their final structure) in order to avoid misfolding or
aggregation of the newly transported proteins (Kim et al., 2013).
mtHSP70 (mitochondrial heat shock 70 kDa protein), also called
mortalin, is a chaperone crucial for the trafficking of proteins into
the mitochondrial matrix, since it forms the core of the import
motor between the TIM23 complex and the matrix. Mortalin also
interacts with HSP60 (heat shock 60 kDa protein), one of the
most important components of the protein folding machinery in
the matrix, helping with the proper folding of newly imported
proteins (Deocaris et al., 2006). The HSP60 and HSP10 (heat
shock 10 kDa protein) machineries form two stacked rings in the
mitochondrial matrix that allow accommodation of the unfolded
polypeptide following the hydrolysis of ATP, assisting henceforth
its proper folding (Walter, 2002; Okamoto et al., 2017). TRAP1
(tumor necrosis factor receptor-associated protein 1), another
molecular chaperone present in the matrix, was first identified
as a member of the HSP90 (heat shock 90 kDa protein) family
because of its high degree of sequence and structural similarity.
HSP90 and TRAP1 both have an N-terminal targeting sequence
and an ATP-binding domain, but TRAP1 displays different
functional characteristics (Song et al., 1995) and is suggested to
play an important role in preventing ROS-dependent cell death
(Gesualdi et al., 2007). In the intermembrane space, the small
TIM chaperones assist the transfer of polypeptides through this
compartment (Webb et al., 2006).
Another critical component of mitochondrial quality control
relies on proteolytic systems located in different mitochondrial
compartments. Together with chaperones, these systems
participate in the import and trafficking of proteins from
the cytosol into the mitochondria. Mitochondrial processing
peptidase (MPP) is the main peptidase responsible for cleaving
the targeting signals of preproteins. After MPP processing, other
peptidases can act, such Oct 1 (octapeptidyl aminopeptidase
1) which removes an octapeptide (Gakh et al., 2002) and Icp55
(intermediate cleaving peptidase of 55 kDa) which removes
a unique amino acid to stabilize the mitochondrial proteins
(Vögtle et al., 2009). Besides their role in protein trafficking
through the mitochondria, mitochondrial proteases are required
to degrade misfolded, damaged, and unfolded proteins that are
no longer capable of being refolded by chaperones, as well as
process proteins that have been imported into the mitochondria.
ATP-dependent proteases hydrolyse ATP to disassemble, unfold
and sequester their substrates in compartments where they
are degraded. Both iAAA and mAAA (ATPases associated
with diverse cellular activities) proteases are inserted into
the inner mitochondrial membrane, with iAAA facing the
intermembrane space and mAAA facing the matrix; these
participate in OXPHOS chain subunits’ quality control and
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turnover (Gerdes et al., 2012). LONP1 (Lon protease) and
CLPP (Clp protease proteolytic subunit) are both serine
peptidases acting in the mitochondrial matrix (Haynes et al.,
2007; Quirós et al., 2014). LONP1 homozygous deletion in
mouse causes embryonic lethality, underscoring its crucial
role in cellular homeostasis (Quirós et al., 2014). Once the
ATP-dependent proteases act, oligopeptidases further process
the substrates. The ATP-independent proteases HTRA2 (high
temperature requirement protein A2) and ATP23 are located
in the intermembrane space and participate in the protein
quality control of this compartment (Clausen et al., 2011;
Quirós et al., 2015). These proteases are highly regulated
and are able to modulate many biochemical activities such as
protein importation, cardiolipin metabolism, mitochondrial
gene expression, and mtDNA stability (Quirós et al., 2015).
For instance, HTRA2 also has a role during apoptosis, since
it can be released from the intermembrane space to relieve
the inhibition of cytosolic caspases by binding to inhibitors of
apoptotic proteins in the cytosol (Hegde et al., 2002; Verhagen
et al., 2002). HTRA2 can also mediate caspase-independent
cell death through its own protease activity (Hegde et al.,
2002).
Mitochondrial Protein Quality Control and
Parkinson’s Disease
Several studies have linked a deficit of mitochondrial import
with the accumulation of α-synuclein within the mitochondria.
Most α-synuclein is soluble and resides in the cytoplasm.
However, some years ago, Devi et al. (2008) reported the
presence of a “cryptic” N-terminus MTS in the human α-
synuclein protein sequence. They also observed an increased
accumulation of α-synuclein in mitochondrial fractions from
post-mortem SNpc of PD patients although which protein
of the import machinery interacts with α-synuclein is still
under investigation. Authors showed that α-synuclein can be
translocated into the mitochondria using physiological import
machinery, particularly the TOM complex (Devi et al., 2008).
Another study suggested the interaction of α-synuclein with
Tom40 and SAM50 (McFarland et al., 2008), while Bender et al.
(2013) reported decreased Tom40 protein levels in post-mortem
human midbrain samples and in the α-synuclein transgenic
mouse model. Moreover, the overexpression of Tom40 in α-
synuclein-accumulating cells and in the α-synuclein transgenic
mouse model resulted in decreased α-synuclein levels. However,
no mechanism was elucidated and import was not measured
(Bender et al., 2013). On the other hand, another study
recently linked α-synuclein with Tom20; the authors described
an α-synuclein-specific interaction with Tom20 in nigrostriatal
dopaminergic neurons of different genetic and pharmacological
PD models and in human post-mortem tissue. This interaction
was prevented by knocking down α-synuclein. Using in vitro
models, oligomeric, dopamine-modified, and phosphomimetic
mutant α-synuclein were able to impair protein import
and induce mitochondrial dysfunction. Moreover, α-synuclein
disrupts the normal Tom20-Tom22 interaction, possibly by
binding to the MTS receptor site in Tom20 (Di Maio et al., 2016;
FIGURE 3 | Mitochondrial protein quality control (MQC) in PD and HD.
Mitochondrial function and cellular metabolism are dependent on maintenance
of the mitochondrial proteome. It is critical to ensure that the mitochondrial
proteome is correctly regulated depending on cellular demands, and this is
achieved by protein import and protein quality control. Different import
pathways and machineries exist for precursor translocation into the
mitochondria. Mitochondrial precursor proteins begin their journey in the
cytosol and are delivered to the translocase of the outer membrane (TOM)
complex. Precursor proteins containing a positively charged N-terminal
presequence are then delivered to the translocase of the inner membrane 23
(TIM23) complex for their translocation into or across the inner mitochondrial
membrane in a membrane potential (1ψ)-dependent manner. Each
mitochondrial compartment has its own quality control machinery. The link
between MQC and neurodegenerative diseases is still under investigation, but
some studies already have shown specific deficits linked to particular
diseases. Although mitochondrial protein import and quality control may have
been traditionally investigated independently, the overlap between the two is
now clear and mitochondrial protein homeostasis cannot be sustained without
both of these processes.
Figure 3). These results tie in two pathogenic characteristics of
PD: α-synuclein accumulation and mitochondrial dysfunction.
However, very few reports have linked PD with mitochondrial
protein import, and they seem to contradict each other, making
it necessary to clarify the exact role that α-synuclein plays
under normal and pathogenic conditions, and whether complex
I inhibition can also impair the translocation of proteins into
mitochondria.
One of the first clues linking PD to molecular chaperones
was the observation of decreased mortalin levels in the SN
of PD patients. Using proteomics, Jin et al. (2006) reported a
significant decrease of mortalin levels in mitochondria-enriched
fractions from the SN of PD patients compared to age-matched
controls (Jin et al., 2006; Figure 3). Three variants in the mortalin
gene (HSP9), two missense (R126W and P509S) and a 17 kb
insertion in intron 8, were found in 3 patients from a Spanish
cohort but in none of the controls, suggesting a genetic link
between mortalin and PD. The missense variants consisted of
an amino acid change in the actin-like ATPase domain and in
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the HSP peptide binding domain of the protein, both amino
acids being highly conserved between HSP70 members from
different species (De Mena et al., 2009). A German cohort
was also screened for mortalin variants, with one variant,
A476T, suggested to act as a risk factor for PD together
with the previously reported variants. Cells overexpressing PD-
associated variants of mortalin showed increased ROS levels
after proteolytic stress compared to cells expressing wild-type
mortalin. Moreover, mitochondrial dysfunction induced by
knock-down of mortalin could only be rescued by wild-type
mortalin but not by PD-associated variants (Burbulla et al.,
2010). Some of these variants were mimicked in yeast, thus
unraveling the presence of a wide range of mitochondrial
alterations and further reinforcing mortalin involvement as a
susceptibility factor for PD (Goswami et al., 2012). Mortalin has
been found to interact with several proteins linked to genetic
PD, such as DJ-1 (Jin et al., 2007; Burbulla et al., 2010), α-
synuclein (Jin et al., 2007), or Parkin (Davison et al., 2009).
Interestingly, PINK1 or Parkin overexpression in mortalin-
knock down cells rescued the mitochondrial phenotype, thus
suggesting that mortalin might also participate in the PINK1-
Parkin pathway (Yang et al., 2011; Burbulla et al., 2014). However,
in recent years, mortalin’s role in the pathogenesis of PD has
been questioned. In the screening of a cohort of 139 early-
onset PD patients, only one missense change in the PD group
and another in the control group were found, suggesting that
mortalin variants may not be a major determinant of early-
onset PD (Freimann et al., 2013). Another study of 500 PD
patients and 500 controls from a Korean population revealed no
significant association of HSP9 variants with PD (Chung et al.,
2017).
While the most accepted PINK1 substrates are ubiquitin and
Parkin, TRAP1 was the first in vivo target identified for PINK1,
linking mitochondrial protein quality control and PD. PD-
linked PINK1 mutations (G309D, L347P, and W437X) abolished
basal and oxidative stress-induced TRAP1 phosphorylation
in vitro, thus impairing PINK1’s cytoprotective effect against
oxidative stress (Pridgeon et al., 2007). The authors revealed
that PINK1 overexpression protects cells against oxidative stress-
induced apoptosis by suppressing mitochondrial cytochrome c
release; this protective action depends on the PINK1-dependent
phosphorylation of TRAP1 (Pridgeon et al., 2007). Moreover,
Drosophila TRAP1-null mutants present some features similar
to PINK1 and Parkin null mutants; TRAP1 is able to partially
rescue mitochondrial impairment in Parkin mutant flies and
vice versa, suggesting that TRAP1 might work in parallel with
Parkin in Drosophila (Costa et al., 2013). In human SH-SY5Y
cells, TRAP1 was able to rescue mitochondrial dysfunction
upon siRNA-induced silencing of PINK1 but not of Parkin
(Zhang et al., 2013). Taken together, these data suggest that
TRAP1 works within the PINK1-Parkin pathway to maintain
mitochondrial integrity, and is also altered in the presence of
PINK1 or Parkin loss-of-function mutations. TRAP1 was also
decreased in A53T α-synuclein-expressing flies, resulting in an
increased sensitivity to oxidative stress andmotor alterations that
were rescued after TRAP1 overexpression, thus providing a link
between PINK1 and α-synuclein through TRAP1 (Butler et al.,
2012). PINK1 also interacts with HSP60 (Rakovic et al., 2011)
and its protein levels are decreased in PINK1 null cells, which
was associated with complex IV deficit (Kim et al., 2012). The
protease LONP1 is responsible for the degradation of oxidized
proteins. MPTP-intoxicated mice displayed increase expression
of LONP1 in the ventral mesencephalon concomitantly with
the presence of oxidized proteins and dopaminergic cell loss.
Moreover, LONP1 activity was inactivated by increased ROS
levels, raising the possibility that LONP1 dysfunction represents
an early event in the pathogenesis of PD (Bulteau et al., 2017).
Mutations in the gene encoding HTRA2, another protease,
were reported in PD patients. These mutations do not affect
the localization of the protein, but instead affect its proteolytic
activity, resulting in increased mitochondrial susceptibility
(Strauss et al., 2005). Mice lacking HTRA2 expression develop
a specific neurodegeneration of striatal neurons together with a
parkinsonian phenotype (akinetic and rigid syndrome, showing
a lack of coordination, decreased mobility and tremor) leading
to early death, thus challenging the notion that HTRA2 is a
major regulator of apoptotic cell death (Martins et al., 2004).
HTRA2 phosphorylation increases its proteolytic activity in a
PINK1-dependent manner, suggesting that these proteins might
be part of the same stress-sensing pathway (Plun-Favreau et al.,
2007). In the same way, drosophila HTRA2 mutants develop
a similar phenotype to those of PINK1 and Parkin mutants,
and HTRA2 was able to rescue the PINK1 phenotype, also
suggesting that HTRA2 and PINK1 might act in the same
pathway (Tain et al., 2009), but independently from Parkin
(Whitworth et al., 2008). TRAP1 might work as a downstream
effector in this pathway since HTRA2 and TRAP1 can interact
with each other; however, this interaction does not involve the
protease activity of HTRA2 (Fitzgerald et al., 2017). Another
protease, rhomboid-7, was found to act upstream of PINK1 and
HTRA2 by cleaving their precursor forms (Whitworth et al.,
2008). Other studies, however, reported no association of HTRA2
variants with PD (Simón-Sánchez and Singleton, 2008; Krüger
et al., 2011).
Mitochondrial Protein Quality Control and
Huntington’s Disease
Huntingtin fragments have been reported to be in close
apposition to mitochondria in cellular and animal models of
HD (Gutekunst et al., 1998; Choo et al., 2004; Orr et al., 2008)
as well as in brain mitochondria of the caudate nucleus of
HD patients (Yano et al., 2014) suggesting a direct role of
mutant huntingtin in mitochondrial dysfunction. Localization of
mutant huntingtin to brain mitochondria from mouse has been
reported to impair protein import through the interaction with
TIM23 complex. Importantly, mutant huntingtin association
with TIM23 complex was not present with wild-type huntingtin,
suggesting a role for polyglutamine domains in the interaction
(Figure 3). Interestingly, import deficiency is present in highly
purified synaptosomal mitochondria from presymptomatic R6/2
mice, thus indicating that the deficiency represents an early
deficit in a subset of mitochondria where high energetic demands
are placed, suggesting that they are more sensitive to these
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mutations. The rescue of mitochondrial protein import by
lentiviral delivery of Tim23, Tim50, and Tim17a, prevented
mitochondrial dysfunction and cell death in mutant huntingtin-
expressing neurons (Yano et al., 2014). The presence of mutant
huntingtin with 111 polyglutamine repeats also seems to
impair the mitochondrial disulfide relay system (MDRS) in
mouse striatal cells. Specifically, Napoli et al. (2013) reported
a decrease in FAD-linked sulfhydryl oxidase augmenter of
liver regeneration, also called Erv1, and Mia40 (mitochondrial
intermembrane space import and assembly protein 40), together
with one of its downstream substrates, Cox17, in total cell lysates.
This deficit was concomitant with the presence of a disrupted
mitochondrial morphology, lower mtDNA copy number and
increased deletions, lower complex I, IV, and V activities,
decreased ATP production and increased oxidative stress (Napoli
et al., 2013). Importantly, MDRS is in charge of the translocation
of some complex I and complex IV proteins (Mesecke et al.,
2005) and small TIM chaperones (Tim8, 9, 10, and 13) (Lutz
et al., 2003), some of which are part of TIM22 complex, which,
in turn, is responsible for the insertion of other translocases. This
suggests that an initial deficit in MDRS could lead to an altered
downstream import pathway (Figure 3). However, the reported
study presents some limitations such as the use of only in vitro
models and the absence of any mechanistic description. It is true,
though, that an impairment of the mitochondrial import system
can hamper the translocation of proteins involved in the TCA
cycle, OXPHOS, and antioxidant defenses, among others, giving
rise to decreases in ATP production and ROS levels, both classical
hallmarks of HD.
A missense mutation (S276C) in the protease domain of
HTRA2 was discovered to be the cause of motor neuron
degeneration 2, a spontaneous recessively inherited mutation
that appeared in the C57BL/6J inbred background. Interestingly,
this mutation leads to specific degeneration of striatal neurons
(Jones et al., 2003), suggesting that those neurons are particularly
vulnerable to HTRA2 deficits and indicating that this protein
could play a role inHD. In a study comparing the gene expression
profiles of three types of neurons expressing wild-type or mutant
huntingtin, HTRA2 mRNA was specifically downregulated only
in striatal neurons with mutant huntingtin (Tagawa et al., 2007).
HTRA2 is downregulated in primary striatal neurons and in
striatal neurons of R6/2 mutant huntingtin-transgenic mice at
the presymptomatic stage, but not in the cortex or cerebellum.
Moreover, the overexpression of HTRA2 in primary neurons
protected against mutant huntingtin-induced cell death, while
the suppression of HTRA2 renders those neurons susceptible
to mutant huntingtin. These data suggest that the selective
reduction of HTRA2 in striatal neurons could be linked to their
selective vulnerability in HD pathology (Inagaki et al., 2008).
While it is clear that proteostasis is altered in HD, it remains
uncertain whether the aggregates present are the main mediators
of neuronal dysfunction. Those aggregates can have a dual role,
on one hand sequestering the toxic protein, but on the other,
acting as a hub to incorporate several proteins. While molecular
chaperones are the first line of defense against protein aggregates,
expression of expanded polyglutamine peptides leads to impaired
protein folding capacity. However, no specific alteration in
mitochondrial molecular chaperones has been reported so far in
the context of HD.
MtUPR: A New Piece in the
Neurodegeneration Puzzle?
As discussed above, the mitochondrial proteome is encoded
by both mitochondrial and nuclear DNA. Proteostatic stress
can arise for a variety of reasons: (i) when there is a
high input of nuclear-encoded mitochondrial proteins that
need to be folded, (ii) imbalance between the nuclear and
the mitochondrial genome, or (iii) oxidative stress that
modifies endogenousmitochondrial proteins.Mitochondria have
developed their own mechanisms (such as the one present in
the endoplasmic reticulum, ER) to respond to this proteostatic
stress, called the mitochondrial Unfolded Protein Response
(mtUPR). This response is a mechanism of mitochondrial to
nucleus communication (Martinus et al., 1996) to activate a
transcriptional program for mitochondrial homeostasis (Zhao
et al., 2002).
The first characterization was made in mammalian cells
and uncovered a transcriptional response characterized by
the upregulation of nuclear genes encoding for mitochondrial
chaperones (HSP60, HSP10, mtDnaJ) and CLPP protease (Zhao
et al., 2002). However, the following studies have used C. elegans
to further analyze the mtUPR. One of the suggested models for
mtUPR activation in C. elegans is based on Clpp-1 (C. elegans
homolog of CLPP protease) dependent degradation, which
generates small peptides that are pumped out through the HAF-1
transporter [HAlF transporter (PGP related) familymember] and
contribute to the downstream signaling of mtUPR by triggering
the relocalization of transcription factor DVE-1 (defective
proventriculus in Drosophila homolog family member) and
UBL-5 (ubiquitin-like protein 5) to the nucleus (Haynes et al.,
2007, 2010; Haynes and Ron, 2010). HAF-1 is also suggested
to work by modulating the stress activated transcription
factor ATFS-1 import. ATFS-1 is a bZIP transcription factor
normally imported into mitochondria and degraded by Lon
protease. ATFS-1 has also a nuclear localization signal and
upon mtUPR activation, its trafficking to mitochondria is
impaired, leading to its translocation into the nucleus and
subsequent transcriptional activation of several genes that are
protective against mitochondrial dysfunction (Nargund et al.,
2012). Therefore, ATFS-1 functions as a sensor of mitochondrial
import efficiency, implying that any condition that hampers
mitochondrial protein import activity could potentially activate
mtUPR (Chacinska et al., 2009; Nargund et al., 2012).
While the mtUPR has been extensively investigated in
C. elegans, it is not clear how this response occurs in mammals.
In cell lines, different interventions activate CHOP (CCAAT-
enhancer-binding protein homologous protein) and C/EBPβ
(CCAAT/enhancer binding protein β) transcription factors,
which heterodimerize, bind to target promoters on a CHOP
binding site, and activate the expression of mtUPR genes
(Aldridge et al., 2007). Recently, ATF5 (cyclic AMP-dependent
transcription factor 5), a bZIP transcription factor, was proposed
to act like ATFS-1 in C. elegans (Fiorese et al., 2016). Importantly,
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in response to mitochondrial stress in both C. elegans and
mammals, there is an increased phosphorylation of eIF2α
(eukaryotic translation initiation factor 2 α) resulting in a
reduction of protein synthesis (Baker et al., 2012; Martínez-Reyes
et al., 2012; Michel et al., 2015; for mtUPR review see Schulz and
Haynes, 2015; Fiorese and Haynes, 2017). In summary, mtUPR
is emerging as a stress response pathway, which coordinates two
different compartments, the nuclear and the mitochondrial, to
promote mitochondrial health.
Several pieces of evidence have linked mtUPR with PD,
but they are mostly circumstantial since mtUPR regulation
in mammals is not fully understood. What is clear is that
parkinsonian toxins such as rotenone or MPP+ (complex I
inhibitors), as well as paraquat (a ROS inducer), are potent
mtUPR inducers, indicating that PD pathogenesis shares
common alterations with mtUPR induction, thus raising the
possibility that the mtUPR response is impaired in PD and
worsens mitochondrial dysfunction (de Castro et al., 2010,
2011). A reduction in protein synthesis, which is one of the
consequences of mtUPR activation, rescues many of the defects
in flies lacking PINK1 (Liu and Lu, 2010), while Drosophila
flies overexpressing a mutant OTC (ornithine transcarbamylase)
protein prone to aggregation develop mitochondrial dysfunction
phenotypes similar to PINK1 and Parkin mutants (Pimenta
de Castro et al., 2012), further confirming the pathogenic role
of protein misfolding in PD. To this end, analysis of post-
mortem brains from PD patients carrying PINK1 mutations
revealed enhanced levels of misfolded components of the
mitochondrial respiratory chain as well as increased levels of
the mtUPR marker of activation HSP60 (Pimenta de Castro
et al., 2012). Another link between mtUPR and PD is mediated
by the association of HTRA2 with PD. In mice, deletion of
HTRA2 results in the accumulation of unfolded proteins in the
mitochondria and leads to neurodegeneration (Moisoi et al.,
2009). However, the role of HTRA2 mutations in familial PD
remains controversial.
The mtUPR pathway is generally regarded as beneficial
for cellular homeostasis, especially in response to genetic or
environmental challenges; however, some reports have started
to challenge this view, indicating that the mtUPR pathway
could be detrimental to the cell under some circumstances.
Recently, Martinez et al. (2017) studied the mtUPR pathway in
a C. elegans model of PD, through the expression of different
forms of α-synuclein. α-synuclein PD-associated variants (A53T
and A30P) were able to induce mtUPR machinery, and this
induction was sustained over time. Importantly, overexpression
and overactivation of ATFS-1 over time, which lead to
mtUPR signaling, was found to be detrimental and to induce
neurodegeneration in C. elegans dopaminergic neurons. In
addition, the co-expression of α-synuclein and overactivation
of the mtUPR potentiate α-synuclein toxicity (Martinez et al.,
2017). Taken together, while these observations challenge the
mainstream view ofmtUPR as a protective pathway, more studies
are needed to fully understand the role of mtUPR in the context
of PD.
So far there are no data linking HD with mtUPR. However,
given the discovery that mutant huntingtin is able to block
mitochondrial protein import, which is thought to be, at least in
C. elegans, an important sensor of mitochondrial homeostasis, it
is plausible that mtUPR could play a role in HD.
REGULATION OF THE MITOCHONDRIAL
NETWORK: AT THE CROSSROADS OF
MITOCHONDRIAL DYNAMICS,
MITOPHAGY, MITOCHONDRIAL
BIOGENESIS, AND MITOCHONDRIAL
TRANSPORT
Mitochondria are dynamic organelles whose structure varies
constantly from a tubular network to individual mitochondria.
This mitochondrial network is controlled by the balance between
various regulated processes: mitochondrial dynamics that control
mitochondrial fusion and fission, de novo mitochondrial
biogenesis, and the elimination of unwanted mitochondria by
mitophagy (Ploumi et al., 2017; Figure 4). While mitochondrial
fusion is believed to favor mitochondrial biogenesis by the
exchange of new proteins and mtDNA between the merging
organelles, mitochondrial fission is considered to be a process
that isolates dysfunctional mitochondria so that they can be
cleared by mitophagy.
Mitochondrial Fusion
Mitofusin 1 and mitofusin 2 (Mfn) are dynamin-like GTPases
that control outer membrane fusion, whereas dynamin-like
120 kDa protein, encoded by the OPA1 gene is the dynamin-
like GTPase in charge of inner membrane fusion (Mishra
and Chan, 2014; Figure 4). Both Mfn have redundant roles
but with certain features: (i) Mfn1, but not Mfn2, is needed
for OPA1-mediated inner membrane fusion (Cipolat et al.,
2004); (ii) Mfn2 mutations cause Charcot-Marie-Tooth disease
type 2A, a peripheral neuropathy characterized by progressive
degeneration of the peripheral nerves (Züchner et al., 2004);
and (iii) in addition to its role in mitochondrial fusion, Mfn2
plays also a key role in mitochondria-ER tethering (de Brito
and Scorrano, 2008). For the complete fusion of mitochondria,
the inner mitochondrial membrane must fuse as well. OPA1
is a dynamin-like GTPase protein anchored to the inner
mitochondrial membrane that exposes the bulk of the protein to
the intermembrane space. Different OPA1 variants, determined
by alternative-splicing and proteolytic cleavage, regulate the
balance between fusion and fission. The processing of OPA1 by
OMA1 (overlapping activity with m-AAA protease) and the i-
AAA protease YME1 is central to the regulation of OPA1 activity,
while the balance between long-OPA1 (L-OPA1) and short-OPA1
(S-OPA1) maintains normal mitochondrial morphology. While
L-OPA1 is sufficient to mediate complete mitochondrial fusion,
the activation of OMA1-dependent processing of OPA1 in the
absence of YME1 leads to mitochondrial fission (Anand et al.,
2014). Upon apoptotic stimuli, a complete conversion of L-OPA1
to S-OPA1 takes place, inhibiting mitochondrial fusion (Song
et al., 2007). Hence, OMA1-mediated degradation of OPA1 is
considered a general cellular stress response.
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FIGURE 4 | Mitochondrial dynamics. Mitochondrial fusion and fission control mitochondrial number and size. Fission is mediated by dynamin-related protein 1 (Drp1)
and mitochondrial fission-1 protein (Fis1). Mitofusins (Mnf) 1 and 2 are involved in the fusion of the outer membrane, whereas protein optic atrophy type 1 (OPA1)
regulates the fusion of the inner membrane. Mitochondrial biogenesis is the process by which cells increase their individual mitochondrial mass to increase the
production of ATP as a response to greater energy demand. In neurons, mitochondria are recruited to subcellular compartments distant from the cell body, such
axons and dendrites, by active transport along microtubules and actin filaments. Selective autophagic degradation of mitochondria (i.e., mitophagy) involves the
recruitment of damaged mitochondria into a pre-autophagosome structure via a PINK1/Parkin-dependent process. When mitochondrial deterioration is mild and
without global mitochondrial depolarization, local removal of mitochondrial content can be achieved by the generation of mitochondrial-derived vesicles (MDV) that
bud-off from the mitochondria and contain matrix components. Both MDVs and PINK1/Parkin-targeted mitochondria are then delivered to lysosomes for degradation.
Mitochondrial Fission
Mitochondrial fission facilitates the segregation of damaged
mitochondria from a healthy network and mitochondrial
transport through neuronal processes. Dynamin-related protein
1 (Drp1) is a cytosolic protein that is recruited to the OMM,
where it oligomerizes to form ring-like structures, which upon
GTP hydrolysis facilitate membrane constriction (Koirala et al.,
2013; Figure 4). Additional adaptors are required for Drp1
recruitment to the mitochondrial surface, such as mitochondrial
fission protein 1 (Fis1), mitochondrial fission factor (Mff) and
the 49 and 51 kDa mitochondrial dynamics proteins (MiD49
and MiD51) (Losón et al., 2013). Mitochondrial fission occurs
at ER-mitochondrial contact sites, where ER tubules mediate
constriction before Drp1 recruitment, indicating a role for ER
tubules in defining division sites (Friedman et al., 2011). Less-well
understood is the fission of the inner mitochondrial membrane
and whether Drp1-mediated outer membrane constriction can
also lead to inner membrane scission is still unknown. However,
S-OPA1 fragment accumulation does favormitochondrial fission.
This discovery opens a new area of study in the field of
mitochondrial fission, since further investigation is needed
to understand the precise role of S-OPA1, together with its
processing-peptidases, in regulating mitochondrial dynamics.
Mitophagy
The accumulation of dysfunctional mitochondria is suggested
to play a key role in the pathology of neurodegenerative
diseases. Impaired mitochondria can be selectively targeted and
eliminated through a process termed mitophagy. Mitophagy
is a highly specialized type of autophagy that consists of
three steps: recognition of the mitochondrion that needs to be
cleared, formation of the autophagic membrane that surrounds
the organelle, and fusion of the mito-autophagosome with
the lysosome. The classical pathway to flag mitochondria for
degradation involves PINK1 and Parkin and has been reviewed
elsewhere (Pickrell and Youle, 2015; Martinez-Vicente, 2017;
McWilliams and Muqit, 2017; Misgeld and Schwarz, 2017;
Figure 4). Briefly, PINK1 is constitutively imported inside
healthy mitochondria, cleaved (Whitworth et al., 2008; Jin
et al., 2010; Meissner et al., 2011; Greene et al., 2012) and
degraded by the proteasome (Yamano and Youle, 2013), so upon
mitochondrial protein import impairment, PINK1 accumulates
in the outer membrane of the dysfunctional mitochondrion
and directly phosphorylates ubiquitin chains linked to the
outer membrane proteins at Ser65. The presence of phospho-
ubiquitins stimulates the recruitment and activation of Parkin,
which is phosphorylated as well by PINK1 leading to its
complete activation (Kondapalli et al., 2012; Shiba-Fukushima
et al., 2012; Kane et al., 2014; Kazlauskaite et al., 2014; Koyano
et al., 2014). As an E3-ubiquitin ligase, Parkin ubiquitinates
many substrates with K48- and K63-linked ubiquitin chains
(Ordureau et al., 2015). K63-chains recruit autophagy adaptor
receptors such as sequestrome 1 (SQSTM1, also known as p62),
NBR1 (neighbor of BRCA1 gene 1), OPTN (optineurin), or
NDP52 (nuclear dot protein 52), while K48-chains might lead
to the degradation of some outer mitochondrial proteins, which
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helps to control mitochondrial motility and dynamics during
the process (Komander and Rape, 2012; Lazarou et al., 2015).
Mitophagy receptors connect the mitochondria to be eliminated
with LC3-II (microtubule-associated protein 1A/1B light chain
3B), the main component of the autophagosomal membrane
(Wild et al., 2014).
Mitophagy extends well beyond the so-called PINK1-
Parkin pathway. In fact, proteins in the OMM can act as
mitophagy adapters under certain conditions. Nix (NIP1-
like protein X, also known as BNIP3L), is induced upon
hypoxia together with Bcl2/E1B 19 kDa-interacting protein 3
(BNIP3); this triggers opening of the mitochondrial permeability
transition pore, depolarization, and LC3/GABARAP (GABAA
receptor-associated protein) recruitment for the autophagosome
formation (Zhang and Ney, 2009; Novak et al., 2010). FUNDC1
(Fun14 Domain Containing 1), an OMM-protein, has also
been implicated in hypoxia-induced mitophagy. FUNDC1
phosphorylation regulates the affinity of the FUNDC1-LC3
interaction, where dephosphorylation increases this interaction
and leads to mitophagy (Liu et al., 2012a). Other mitochondrial
proteins have been described to act as mitophagy receptors
by recruiting the autophagosomal machinery (Martinez-Vicente,
2017).
Mitochondrial Biogenesis
The need to degrade dysfunctional mitochondria must be
balanced with the generation of de novo mitochondria to keep
a healthy network (Figure 4). Mitochondrial biogenesis requires
a complex coordination of the nuclear and mitochondrial
expression programs. PGC-1α is the master regulator of
mitochondrial biogenesis; it interacts with and coactivates
several transcription factors such as nuclear respiratory factors
1 and 2 (NRF1 and NRF2), estrogen-related receptor alpha
(ERRα), ying and yang 1 (YY1), myocyte enhancer factor 2C
(MEF2C), peroxisome proliferator-activated receptors (PPAR),
and many others coordinating mitochondrial biogenesis and
oxidative metabolism (Wu et al., 1999; Scarpulla, 2006, 2011).
NRF1 and NRF2 frequently work together to up-regulate the
transcription of several nuclear-encoded genes with essential
mitochondrial functions, and to induce the expression of
mitochondrial transcription factor A (TFAM) (Virbasius et al.,
1993; Scarpulla, 2008), which initiates the transcription and
replication of mtDNA given its ability to bind and bend DNA
without sequence specificity (Ekstrand et al., 2004). Through the
regulation of TFAM levels, PGC-1α can regulate the expression
of mitochondrial genes (Scarpulla, 2008).
Mitochondrial Transport
Mitochondrial transport is crucial for the distribution of
mitochondria throughout the neuron, from the cell body to the
presynaptic terminals, and to accomplish the resupply of newly
synthesized mitochondria and mitochondrial proteins (Saxton
and Hollenbeck, 2012; Schwarz, 2013; Misgeld and Schwarz,
2017; Figure 4). Large numbers of mitochondria localize at the
presynaptic terminals, probably reflecting the elevated levels
of ATP required for synaptic transmission and the need to
regulate Ca2+ homeostasis during intense synaptic activity
(Keating, 2007). Mitochondrial transport relies on microtubule-
based motors—the anterograde kinesin-1 motor (Kif5B) and
the retrograde dynein motor—attached to the mitochondria
by the complex formed by Miro and a mitochondrion-kinesin
linker protein, Milton (Wang and Schwarz, 2009). Stationary
mitochondria are held in place by anchoring proteins, such as
syntaphilin, through their interaction with microtubules (Kang
et al., 2008).
Organellar Quality Control and PD
Alterations in the mitochondrial fusion/fission balance have not
yet been directly demonstrated in PD. However, our group
and others have shown that the parkinsonian neurotoxins
6-OHDA (6-hydroxydopamine), rotenone and MPP+ induce
mitochondrial fragmentation (fission) and cell death in neuronal
cultures (Barsoum et al., 2006; Meuer et al., 2007; Gomez-Lazaro
et al., 2008; Ramonet et al., 2013). Supporting a pathogenic role
for mitochondrial fission, genetic inhibition of pro-fission Drp1
or pro-fusion Mfn1 or OPA1 overexpression are able to prevent
cell death induced by these neurotoxins.
The potential importance of mitochondrial dynamics in PD
was revealed in part by the identification of different autosomal
recessive and autosomal dominant genes linked to PD. α-
synuclein overexpression leads to mitochondrial fragmentation
in several models, ranging from C. elegans to neuroblastoma cell
lines (Kamp et al., 2010; Nakamura et al., 2011; Butler et al.,
2012; Xie and Chung, 2012; O’Donnell et al., 2014), but no
direct mechanism has been elucidated so far. It was suggested
that binding of α-synuclein to sodium dodecyl sulfate micelles
induces a reduction in themembrane curvature (Perlmutter et al.,
2009). This observation reinforces the notion that α-synuclein-
dependent mitochondrial fragmentation may be exerted through
direct association with the mitochondria. Mice overexpressing
A53T α-synuclein present reductions in Mfn1, Mfn2, and Drp1
protein levels in the spinal cord, which correlated with decreased
mitochondrial size (Xie and Chung, 2012). However, upon
Drp1 loss in mice, mitochondrial fragmentation induced by α-
synuclein still occurs (Nakamura et al., 2011; Guardia-Laguarta
et al., 2014). Furthermore, N-terminal disruption of α-synuclein
in human induced pluripotent stem cells led to mitochondrial
elongation in neurons (Pozo Devoto et al., 2017), suggesting
a possible physiological role for α-synuclein in regulating
mitochondrial size through its direct interaction with the fusion-
fission process rather than with fusion-fission machinery.
LRRK2 protein has also been linked to mitochondrial
dynamics, although its exact role remains to be clarified.
Enlarged mitochondria were reported in G2019S mutant LRRK2
overexpression in Drosophila (Ng et al., 2012) and in skin
biopsies from LRRK2G2019Smutation carriers (Mortiboys et al.,
2010). In Drosophila, increased mitochondrial length can be
rescued by Parkin overexpression (Ng et al., 2012), suggesting
that both LRRK2 and Parkin may function in the same pathway
to promote fusion. LRRK2 has also been found to interact
with mitofusins and OPA1 in mitochondrial membranes, while
S-OPA1 levels, but not L-OPA1, are reduced in G2019S PD
brains in contrast to idiopathic PD brains, where no changes
in S-OPA1 are observed (Stafa et al., 2014). However, others
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have shown that wild-type LRRK2 interacts with Drp1 and
that this interaction was exacerbated by the expression of PD-
associated mutants. Moreover, LRRK2 wild-type or G2019S
variant overexpression leads to mitochondrial fragmentation and
clearance through the recruitment of Drp1 (Niu et al., 2012;
Wang et al., 2012). Treatment with an LRRK2 inhibitor of cybrid
cell lines from sporadic and LRRK2 patients (G2019S) leads to
increased mitochondrial elongation and reduced phospho-Drp1
levels (Esteves et al., 2015), further supporting a role for LRRK2
in Drp1-mediated mitochondrial fission.
The PD-related proteins PINK1 and Parkin appear to control
mitochondrial morphology by regulating mitochondrial fusion-
fission events. However, whereas PINK1 and Parkin seem
to promote mitochondrial fission and/or inhibit fusion in
Drosophila, their role in mammals is more controversial (Guo,
2012; Scarffe et al., 2014). While PINK1 and Parkin functions
in mitophagy have been studied extensively, their contribution
to neuronal mitophagy has been challenged recently. Given that
PINK1 and Parkin have been observed to be mutated in familial
forms of PD, one would expect that impaired mitophagy might
be a general theme in the pathogenesis of PD; however PINK1-
and Parkin-knockout mice do not display neurodegeneration
(Palacino et al., 2004; Gautier et al., 2008). Moreover, some
groups have failed to observe Parkin recruitment in neurons
following mitochondrial depolarization (Van Laar et al., 2011), or
reported failure of endogenous Parkin to mediate mitophagy in
neurons and cultured cells (Rakovic et al., 2013). Nonetheless, Cai
et al. (2012) reported Parkin-dependent mitochondrial clearance
in the somatodendritic region of primary cortical neurons
upon CCCP (carbonyl cyanide m-chlorophenyl hydrazone)
treatment (Cai et al., 2012). Besides, Suzuki et al. (2017)
reported dysfunctional mitophagy in dopaminergic neurons
derived from induced pluripotent stem cells from Parkin-
mutated patients (Suzuki et al., 2017). In the MitoPark mouse
model, in which there are clear mitochondrial alterations
such as mitochondrial fragmentation and mitochondrial-derived
aggregates, no evidence of Parkin recruitment to the defective
mitochondria was observed, nor was there any effect of Parkin
loss on the progression of neurodegeneration (Sterky et al.,
2011). Conversely, the absence of Parkin in the Mutator mice
(mice homozygous for a proofreading deficiency in DNA
polymerase γ) led to a robust dopaminergic neuronal loss
(Pickrell and Youle, 2015), suggesting that, at least in some
cases, a basal level of mitochondrial dysfunction is needed
in order to detect the detrimental effects of Parkin loss.
What might be the role of PINK1-Parkin-dependent neuronal
mitophagy in vivo is therefore still a matter of debate since;
(i) most studies use proliferating cell lines, which poorly
reflect the post-mitotic state of degenerating neurons; (ii)
to induce mitophagy, a potent uncoupler (CCCP) is used,
which inducesd a severe mitochondrial depolarization that
rarely happens in vivo; and (iii) PINK1 and Parkin must be
overexpressed in order to detect robust mitophagy. Interestingly,
two in vivo mouse models, the mito-Keima and the mito-QC,
have been recently developed (Sun et al., 2015; McWilliams
et al., 2016). These models, which are based on the use
of fluorescent reporter proteins, enable the visualization of
mitophagy in vivo and might help to finally understand the in
vivo role of PINK1-parkin-dependent mitophagy. Of note, loss
of function of glucocerebrosidase and SREBF1, both proteins
linked to or associated with PD, have been shown to be
linked to mitophagy defects (Osellame et al., 2013; Ivatt et al.,
2014).
PINK1 and Parkin have also been linked to the biogenesis
of a population of MDV. Importantly, this process takes place
faster than mitophagy, suggesting that such a mechanism
may help to preserve the integrity of the organelle while
damaged components are extracted. Parkin seems to
colocalize with MDVs in a PINK1-dependent fashion upon
oxidative stress, and MDVs are targeted to lysosomes
for degradation independently of “typical” mitophagy
mechanisms (McLelland et al., 2014). MDVs transport
specific oxidized mitochondrial cargo, including subunits
of the OXPHOS chain such as COXI, a transmembrane
component of complex IV of the electron transport chain
(McLelland et al., 2014; Sugiura et al., 2014). Interestingly,
VPS35, which is linked to late-onset autosomal dominant PD,
participates in the generation of some MDVs (Braschi et al.,
2010).
Important advances emphasizing the contribution of impaired
mitochondrial biogenesis to PD have recently been made. For
downregulation of nuclear-encoded complex I genes was found
associated with decreased expression of mitobiogenesis factors
in PD frontal cortex, pointing at defects in mitochondrial
biogenesis as another player in mitochondrial dysfunction
(Thomas et al., 2012). Parkin also plays a role in the
mitochondrial biogenesis pathway through the ubiquitination of
Parkin Interacting Substrate (PARIS), leading to its ubiquitin-
dependent degradation. PARIS is a major transcriptional
repressor of PGC-1α expression, with a loss of Parkin in
adult mice leading to PGC-1α downregulation due to PARIS
upregulation, and dopaminergic neurodegeneration (Shin et al.,
2011). The aforementioned study is particularly interesting
since earlier reports failed to detect neurodegeneration in
Parkin germline knock-out models. Here, there is a conditional
knock-out in adult mice, which may suggest that whole
body knock-out since birth may result in the development
of compensatory mechanisms. The authors argue that similar
compensatory mechanisms might occur in PD, accounting
for the age-dependence of neurodegeneration observed in
PD. PGC-1α and NRF-1 mRNAs are downregulated in
the SN and striatum of PD patients, with no changes
in mRNA levels of PARIS or Parkin, indicating that the
upregulation of PARIS protein levels responds to a loss in
the E3 ubiquitin ligase activity of Parkin (Shin et al., 2011).
Decreased PGC-1α protein levels are associated with a loss in
mitochondrial markers (Jiang et al., 2016). Further supporting
the role of PGC-1α in PD, PGC-1α overexpression in adult
conditional Parkin knock-out mice prevents dopaminergic
neurodegeneration (Shin et al., 2011). Moreover, upon Parkin
loss, mice present reduced mitochondrial size and number,
together with structural abnormalities. These mitochondrial
alterations depend on PARIS accumulation, since its loss
rescues the mitochondrial mass (Stevens et al., 2015). This
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data further reinforces the role of the Parkin-PARIS-PGC-
1α axis in mitochondrial biogenesis and homeostasis, and
provide more evidence for the key role of Parkin in the
regulation of mitochondrial quality control. Recently, it was
shown that PINK1 cooperates with Parkin by mediating PARIS
phosphorylation to control its ubiquitination and clearance
by Parkin (Lee et al., 2017). PGC-1α conditional deletion in
adult mice leads to dopaminergic loss in the SNpc together
with a reduction of dopamine in the striatum, highlighting
the role of PGC-1α in neuronal viability in adult mice (Jiang
et al., 2016). PGC-1α polymorphisms are associated with
increased risk and age of onset of PD (Clark et al., 2011).
The tandem PINK1-Parkin also participates in mitochondrial
transport regulation by mediating Miro phosphorylation and
ubiquitination, which targets the protein for proteasomal
degradation (Wang et al., 2011; Liu et al., 2012b). Since PINK1
stabilization in the OMM occurs in damaged mitochondria,
this mechanism is thought to arrest dysfunctional mitochondria,
potentially decreasing their capacity to fuse with healthy ones.
PINK1 and/or Parkin loss would facilitate the trafficking of
dysfunctional mitochondria toward the axon terminals, where
they could hamper energy production. Recent work has linked
the α-synuclein A53T mutation with an altered balance in
anterograde and retrograde transport (Pozo Devoto et al.,
2017), while the LRRK2 R1441C variant is associated with
impaired neuritic mitochondrial transport in SH-SY5Y cells
(Thomas et al., 2017).
Organellar Quality Control and
Huntington’s Disease
In HD, the balance between fusion and fission is aberrantly
shifted toward fission, which is associated with increased
levels of Drp1 and Fis1 mRNA and decreased mitofusins
in striatal and cortical regions (Kim et al., 2010; Shirendeb
et al., 2011). These changes in key proteins controlling
the mitochondrial fission/fusion balance are translated into
mitochondrial fragmentation in HD human tissue and mouse
models (Liot et al., 2009; Shirendeb et al., 2011). The
mechanism leading to exacerbated mitochondrial fission in
the presence of mutant huntingtin seems to involve a direct
interaction with Drp1. In human post-mortem samples and
in transgenic mice lines, mutant huntingtin interacts with
Drp1 with a higher affinity than that of the wild-type
huntingtin. This interaction leads to increased Drp1 enzymatic
activity and mitochondrial fragmentation. The transfection
of a dominant-negative Drp1 mutant (Drp1 K38A) leads
to elongated and uniformly distributed mitochondria and
protects against ATP loss and cell death, further supporting
a role for Drp1 in mitochondrial fragmentation (Wang et al.,
2009; Song et al., 2011; Shirendeb et al., 2012). Consistent
with this hypothesis, Drp1 GTPase activity was increased
in the cortex of HD patients (Shirendeb et al., 2012).
Furthermore, blocking the interaction of Drp1 with Fis1,
which inhibits mitochondrial fission, rescues striatal neuronal
loss, improves motor activity and reduces mortality in R6/2
HD mice (Guo et al., 2013), suggesting that shifting the
balance toward mitochondrial fusion could have a positive
impact on disease progression. Brains of HD patients exhibit
increased levels of S-nitrosylated Drp1 (Haun et al., 2013),
a post-translational modification reported to enhance its
GTPase activity (Cho et al., 2009). Since mutant huntingtin
increases nitric oxide production, it is hypothesized that mutant
huntingtin’s interaction with Drp1 enhances its nitrosylation,
thereby increasing mitochondrial fragmentation in HD (Haun
et al., 2013).
Huntingtin protein plays an important role in the cargo
recognition step in selective autophagy (Ochaba et al.,
2014); the presence of the polyglutamine tract can affect
the efficiency of this step and thus lead to impaired clearance
of damaged mitochondria by mitophagy. Initial work by
Martínez-Vicente et al. described the presence of “empty
autophagosomes” in HD cells, suggesting that mutant huntingtin
somehow impairs the cargo sequestration step, leading to
inefficient cargo loading with lipid droplets and mitochondria
being excluded from autophagic vacuoles (Martinez-Vicente
et al., 2010). Huntingtin acts as a scaffold to bring together
different proteins needed for autophagy to take place,
such as p62 and ULK1 (unc-51 like autophagy activating
kinase 1), which is normally inhibited by its association
with mTORC1 (mammalian target of ramapycin complex
1). Upon exposure to different stresses, UKL1 is released
from mTOR inhibition and interacts with huntingtin in a
kinase-active form (Rui et al., 2015). It is likely, therefore,
that the polyglutamine tract affects huntingtin’s ability to
associate with cargo receptors and autophagy machinery.
While some studies have suggested that the presence of
undigested mitochondria could stem from disturbances in
autophagosomal transport, which is required for lysosomal
fusion to autophagosomes (Wong and Holzbaur, 2014), others
reported decreased LC3-mitochondria colocalization, arguing
in favor of decreased mitophagy due to an impairment in
the targeting of defective mitochondria to autophagosomes
(Khalil et al., 2015). Interestingly, PINK1 overexpression could
partially rescue the mitophagy defect in mouse striatal cells
expressing mutant huntingtin (Khalil et al., 2015). Recent
work has also linked mutant huntingtin with the impairement
of a new form of micro-mitophagy mediated by GAPDH
(glyceraldehydes-3-phosphate dehydrogenase) association
with damaged mitochondria upon oxidative stress (Hwang
et al., 2015). All in all, the ability of mutant huntingtin to
interfere with different quality control process at the level of the
whole mitochondria organelle prevents the correct elimination
of damaged mitochondria, which potentially amplifies the
deleterious cascade.
Studies on axonal transport in several in vitro models
of HD reported impaired mitochondrial trafficking (Trushina
et al., 2004; Chang et al., 2006; Orr et al., 2008). Wild-type
huntingtin is involved in fast axonal trafficking in mammals,
and this function has been attributed to its association with
huntingtin-associated protein-1 (HAP1) (Gutekunst et al., 1998).
HAP1 is an essential neuronal protein that interacts with
dynactin p150 (Engelender et al., 1997) and kinesin light chain
(McGuire et al., 2006). In contrast, mutant huntingtin leads to
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trafficking abnormalities (Gunawardena et al., 2003), but the
exact mechanism for this remains unknown. One possibility
is that mutant huntingtin leads to abnormal interactions with
HAP1, leading to impaired vesicular and organellar trafficking.
Moreover, data from mouse neurons and human HD-affected
brain suggests that large mutant huntingtin aggregates impair
neuronal trafficking by sequestering wild-type huntingtin and
motor proteins from soluble pools (Trushina et al., 2004).
This trafficking defect also affects mitochondrial motility and
appears to correlate with glutamine length (Trushina et al.,
2004), leadingmitochondria to accumulate adjacent to aggregates
and become immobilized (Chang et al., 2006). Moreover, some
polyglutamine-containing N-terminal huntingtin fragments,
caused by proteolytic cleavage, can associate with mitochondria
and, in vitro, interfere in its association with microtubule-
based transport proteins, thus illustrating another mechanism by
which mutant huntingtin can impair mitochondrial trafficking
(Orr et al., 2008). More recently, mitochondrial trafficking
was studied in primary hippocampal neurons from bacterial
artificial chromosome mouse expressing full length human
mutant huntingtin (BACHD mice) (Shirendeb et al., 2012).
The authors found a decreased number of mitochondria
moving anterogradely, together with increased numbers of
mitochondria in the cell soma. Neuronal processes were,
moreover, devoid of mitochondria, thus further documenting
the aberrant mitochondrial transport associated with mutant
huntingtin expression.
As discussed above, early-stage HD patients present decreased
PGC-1αmRNA levels in the striatum but not in the hippocampus
or cerebellum. Expression data from HD caudate tissue showed
reduced expression of 24 out of 26 PGC-1α target genes (Cui
et al., 2006; Weydt et al., 2006), while a splice variant of
PGC-1α, which leads to a 38 kDa protein that complements,
overlaps or prolongs PGC-1α full length action, has been found
to be severely altered in human HD brain and myoblasts, as
well as in mouse and cellular HD models (Johri et al., 2011;
Török et al., 2015). Recently, a coding variant in PGC-1α
was found to be associated with the age of onset of motor
symptoms in men carrying the HD mutation (Weydt et al.,
2014). Moreover, a correlation exists between PGC-1α reductions
FIGURE 5 | Schematic diagram depicting an hypothesized scenario responsible for mitochondrial dysfunction in PD and HD. ROS are continuously produced in vivo
by all body tissues. The presence of mitochondrial translocases, chaperones and proteases within the mitochondrial matrix and intermembrane space acts as a first
line of defense against unfolded and oxidized soluble proteins. Mitochondria unfolded response (mtUPR) is believed to be activated by cytosolic transcription factors
(ATFS-1, UBL-5, DVE-1). Once inside the nucleus, these transcription factors promote the upregulation of genes involved in mitochondrial proteostasis. To maintain a
healthy network, mitochondrial are dynamic and can fuse, divide, and move. Once the accumulation of mitochondrial defects exceeds a threshold, patches of
mitochondria can be removed through the generation of mitochondrial-derived vesicles (MDVs), which transit to the lysosome. Upon complete mitochondrial
dysfunction, the entire organelle can be targeted to the autophagosome via so-called mitophagy. When none of the rescue strategies are able to restore mitochondrial
function, the cell enters its ultimate destiny, apoptosis. Clinical trials using general caspase inhibitors such as CEP-1347 and TCH346 failed, maybe because it was
too late in the process to intervene. Other compounds were tested in clinical trials, from fission inhibition using mdivi to PPARγ activation, but none were able to show
clear treatment benefits. Interestingly, the role of mitochondrial quality control (MQC) in neuronal health is a recently growing subject for investigation, indicating that
MQC might be central to maintain healthy mitochondria. However, until now, no novel therapeutic strategy specifically targeting MQC has been developed. It is clear
that future research focusing on understanding MQC is needed to develop better pharmacological interventions.
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and mitochondrial reductions in HD post-mortem brain (Kim
et al., 2010). In line with this, PGC-1α null mice develop
a neurological phenotype consistent with neurodegeneration,
together with spongiform lesions predominantly in the striatum
(Lin et al., 2004). Pharmacologic activation of PGC-1α expression
resulted in improved behavior, improved survival and reduced
brain, muscle, and brown adipose tissue pathology in R6/2
transgenic and full-length huntingtin mouse models of HD
(Johri et al., 2012; Chandra et al., 2016). These observations
provide further support of the key role that alterations in the
PGC-1α pathway play in mitochondrial dysfunction in HD.
cAMP signaling is a key activator in PGC-1α transcription,
promoting the binding of cAMP response element (CRE)-
binding protein (CREB) or activating transcription factor-
2 to a conserved DNA response element in the PGC-1α
promoter. Mutant huntingtin interferes with the CREB/TAF4
transcriptional pathway in striatal neurons, thus repressing the
CRE-mediated transcription of PGC-1α (Cui et al., 2006; Weydt
et al., 2006). Levels of TORC (Transducers of Regulated CREB
Activity), a CREB coactivator, were decreased in the striatum of
HD patients, mice and cellular HD models (Chaturvedi et al.,
2012).
CONCLUSION
Mitochondria are essential organelles for the maintenance
of neuronal homeostasis. The importance of functional
mitochondria to neurons is highlighted by the fact that situations
leading to mitochondrial dysfunction are often associated with
neurodegenerative diseases. Many of these diseases manifest
later in life, where mitochondria seem to be less functional
(Grimm and Eckert, 2017). Mitochondria are at the center of the
free radical theory of aging by being both a source and target
of ROS. As discussed in this review, the imbalance between
ROS production and antioxidant defense in neurodegenerative
diseases leads to protein, lipid and DNA oxidation, which in
turn affect mitochondrial function. It was previously considered
that when ROS levels exceeded a pathological threshold, this
may trigger cell death by apoptosis (Figure 5). However,
recent developments highlight the increasing potential of
mitochondria to defend themselves against various threats
(Perier et al., 2010, 2013). Different levels of quality control co-
exist within mitochondria to detect and repair defects that affect
mitochondrial performance, before the point of inescapable
cell death is reached: (i) novel, critical roles of mitochondrial
proteases have emerged in neural physiology and pathology
and (ii) mitochondrial dynamics play an important role in
maintaining a healthy organelle population. Thus, impairments
in these quality control systems may lead to the accumulation
of defective mitochondria, as well as inefficient mitochondrial
transport and distribution, leading to synaptic and neuronal
degeneration. However, the more our understanding of protein
quality control activities in mitochondria continues to expand,
the more questions that are raised. How are all the mitochondrial
quality control mechanisms, at the protein and the organelle
levels, inter-connected? As mechanisms that flag defective
mitochondria are thought to be similar, are these pathways
temporarily interlinked and is there crosstalk between them to
coordinate mitochondrial homeostasis?
Despite the many therapeutic advances in PD and HD, no
agent has yet been established that has neuroprotective effects
in either disease. Although apoptosis is potentially a terminal
pathway relevant to both PD and HD, therapeutic targeting
of executioner caspases, despite initially high expectations due
to the availability of pharmacological caspase inhibitors, has
failed to prevent neurodegeneration in clinical trials (Parkinson
Study Group PRECEPT Investigators, 2007; Huntington Study
Group DOMINO Investigators, 2010; Figure 5). Acting before
the terminal phase is reached might represent an effective
neuroprotective therapy that slows or stops disease progression
and prevents the development of cumulative disability (Bové
et al., 2014). Some compounds, which target mitochondrial
dysfunction and mitochondrial quality control, have shown
beneficial effects in mouse models of neurodegenerative diseases
and show great promise for treating patients (Figure 5). Our
current knowledge regarding mitochondrial quality control
continues to evolve, opening novel and exciting research paths
that will likely help to develop clinically effective therapeutic
applications to prevent or combat neurodegenerative diseases.
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